Holen Sie sich die Stockscreener-App
232.75
0.98%
2.25
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$230.50
Offen:
$230.94
24-Stunden-Volumen:
333.79K
Relative Volume:
0.06
Marktkapitalisierung:
$163.62B
Einnahmen:
$24.78B
Nettoeinkommen (Verlust:
$3.68B
KGV:
44.98
EPS:
5.1743
Netto-Cashflow:
$5.29B
1W Leistung:
+3.71%
1M Leistung:
+3.68%
6M Leistung:
+31.31%
1J Leistung:
+4.37%
1-Tages-Spanne:
$230.60
$233.69
1-Wochen-Bereich:
$217.55
$238.13
52-Wochen-Spanne:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Firmenname
Danaher Corp
Sektor
Branche
Telefon
(202) 828-0850
Adresse
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
232.75 | 163.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
681.43 | 251.96B | 45.20B | 6.87B | 6.75B | 18.19 |
NTRA
Natera Inc
|
403.02 | 58.09B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.97 | 49.61B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
279.87 | 46.07B | 16.63B | 1.39B | 2.12B | 8.0674 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-09 | Fortgesetzt | UBS | Buy |
| 2026-06-11 | Eingeleitet | Piper Sandler | Neutral |
| 2026-06-03 | Eingeleitet | DZ Bank | Buy |
| 2026-06-02 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2026-05-26 | Fortgesetzt | Citigroup | Buy |
| 2026-05-15 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2025-03-14 | Hochstufung | Stifel | Hold → Buy |
| 2025-02-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-19 | Eingeleitet | Guggenheim | Buy |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-31 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Eingeleitet | HSBC Securities | Hold |
| 2023-12-13 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2023-12-07 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-01 | Eingeleitet | SVB Securities | Outperform |
| 2023-04-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-10-24 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-17 | Fortgesetzt | Bernstein | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-06-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Eingeleitet | Bernstein | Outperform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-10 | Bestätigt | BofA Securities | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Bestätigt | Goldman | Buy |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-04-07 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-03 | Fortgesetzt | Barclays | Overweight |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Fortgesetzt | Stifel | Hold |
| 2019-10-28 | Bestätigt | Needham | Buy |
| 2019-10-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-19 | Bestätigt | Needham | Buy |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2019-02-25 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-04-20 | Bestätigt | Stifel | Buy |
Alle ansehen
Danaher Corp Aktie (DHR) Neueste Nachrichten
LH vs. DHR: Which Stock Is the Better Value Option? - Zacks Investment Research
Company News for Oct 22, 2026 - Zacks Investment Research
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line - Zacks Investment Research
Danaher (DHR) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research
Danaher stock: At 7.19 percent below its 52-week high, Danaher stock sits at USD 225.35 - ad-hoc-news.de
Danaher earnings on deck as new CEO faces bioprocessing test By Investing.com - Investing.com South Africa
Danaher schedules third-quarter results: Danaher stock is valued at USD 157.8 billion - ad-hoc-news.de
Beckman Coulter Diagnostics appoints Catherine Jennings as president - Manufacturing Chemist
Danaher (DHR) Reports Q3: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
People Moves: Heineken, Danaher, Domino’s & Ericsson - Business Chief
Danaher Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
How Investors May Respond To Danaher (DHR) NVIDIA Lab AI Partnership - Simply Wall Street
Roper Technologies (ROP) vs. Danaher (DHR): Which Is the Better Long-Term Capital Allocator? - Yahoo Finance
Danaher and NVIDIA Partner to Accelerate Autonomous Science - Healthcare Digital
A director reports 46,915 trust-held shares in Danaher (DHR), plus employee stock options. - Stock Titan
Danaher Corp. stock underperforms Friday when compared to competitors - MarketWatch
Danaher, Nvidia Combine Lab Instrumentation and AI to Advance Autonomous Science - Genetic Engineering and Biotechnology News
Danaher (DHR) Teams Up To Bring AI Into Scientific Research Workflows - Yahoo Finance
Danaher’s Stock Is Pricing in a Recovery. Can Its Earnings Deliver? - Yahoo Finance
Danaher stock: TD Cowen lifts target to USD 255.00 for Danaher stock - ad-hoc-news.de
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? - Zacks Investment Research
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? - Yahoo Finance
Seeking Clues to Danaher (DHR) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance
SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock? - Zacks Investment Research
Danaher Corporation (DHR) Stock Forecasts - Yahoo Finance
A Look at Danaher Corp (DHR) After 3.0% Gain -- GF Value $235.89 vs Price $231.50 - GuruFocus
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Danaher Corp Stock (DHR) Moved Up by 3.34% on Oct 15: Drivers Behind the Movement - TradingKey
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
Danaher and NVIDIA partner on AI-driven lab automation - BioXconomy
Danaher teams with NVIDIA to bring AI into scientific instruments - finchannel
Will Third-Quarter Earnings Be the Turning Point for These Two Lagging Healthcare Stocks? - NAI500
Danaher stock may move 6.2% on earnings release next week - Investing.com
For no consideration, Danaher (DHR)’s executive committee chairman waives a stock award. - Stock Titan
For no consideration, Danaher (DHR) chairman waives his stock award. - Stock Titan
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Danaher (DHR) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research
Danaher (DHR) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
What's Going On With Danaher Stock Wednesday?NVIDIA (NASDAQ:NVDA), Danaher (NYSE:DHR) - Benzinga
Danaher Teams Up With NVIDIA, Aims To Bring Accelerated Computing, Physical AI Into Labs - TradingView
Danaher Teams Up With NVIDIA, Aims To Bring Accelerated Computing, Physical AI Into Labs - Stocktwits
Danaher (NYSE:DHR) Sets Up for Breakout With Strong Technical Ratings - ChartMill
Danaher Corporation Announces A Collaboration with Nvidia - marketscreener.com
Danaher and NVIDIA Partner to Integrate AI Into Scientific Instruments - Unite.AI
Danaher Collaborates with NVIDIA to Advance Autonomous Science - Yahoo Finance
NVIDIA and Danaher are working to link AI with lab experiments. The initial work focuses on select instruments. - Stock Titan
Danaher Appoints Daniel Comas and Robert Hershberg to Board of Directors - citybiz
Danaher (DHR) Expands Board to 13 Members, Appoints Daniel Comas and Dr. Robert Hershberg - GuruFocus
Form 8-K DANAHER CORP /DE/ For: Oct 09 - StreetInsider
Finanzdaten der Danaher Corp-Aktie (DHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Danaher Corp-Aktie (DHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rainer M. Blair | Officer |
Aug 21 '26 |
Proposed Sale |
218.85 |
58,255 |
12,749,107 |
0 |
| Zerhouni Elias A. | Director |
Jul 15 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
46,484 |
| FILLER LINDA | Director |
Jul 15 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
28,010 |
| SCHWIETERS JOHN T | Former Director |
Jul 14 '26 |
Proposed Sale |
199.59 |
3,298 |
658,254 |
0 |
| SPOON ALAN G | Director |
May 01 '26 |
Proposed Sale |
174.67 |
1,358 |
237,207 |
0 |
| SPOON ALAN G | Director |
May 01 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
125,452 |
| SPOON ALAN G | Director |
May 01 '26 |
Sale |
174.67 |
1,358 |
237,207 |
124,094 |
| Milosevich Gregory M | Executive Vice President |
Feb 19 '26 |
Option Exercise |
58.59 |
1,320 |
77,339 |
6,419 |
| Milosevich Gregory M | Executive Vice President |
Feb 19 '26 |
Sale |
208.01 |
1,320 |
274,575 |
5,099 |
| Milosevich Gregory M | Officer |
Feb 19 '26 |
Proposed Sale |
208.01 |
1,320 |
274,575 |
0 |
1.13%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):